Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,317.10
(
-0.46%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 219765

Monday, 07/09/2018 3:10:41 PM

Monday, July 09, 2018 3:10:41 PM

Post# of 257484
ASMB starts two phase-2a trials in HBV—trial designs as previously disclosed and discussed on this board:

https://globenewswire.com/news-release/2018/07/09/1534523/0/en/Assembly-Biosciences-Initiates-Two-Phase-2a-Trials-of-ABI-H0731-for-the-Treatment-of-Hepatitis-B-Virus-Infection.html

I’ve been skeptical of what ASBM is trying to show vis-à-vis eradicating cccDNA, which is the main hurdle to overcome in curing HBV with a short course of therapy. (Please see the thread culminating at #msg-141761202 for background.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today